Compare Western Alliance Bancorporation (WAL) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Western Alliance Bancorporation vs State Street SPDR S&P Biotech ETF — how do they compare? Western Alliance Bancorporation trades at $82.6 (market cap $8.89B), while State Street SPDR S&P Biotech ETF trades at $159.35. The key difference: Western Alliance Bancorporation pays a 2.06% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Western Alliance Bancorporation nearer its low. Which is the better fit depends on your goals.
| WAL | XBI | |
|---|---|---|
Market Cap | $8.89B | — |
Sector | Financials | Broad Market / Factor |
52-Week High | $96.08 | $164.28 |
52-Week Low | $66.70 | $86.92 |
Dividend Yield | 2.06% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Western Alliance Bancorporation (WAL) trades at $82.62, up 2.66% today, with a neutral technical signal and bullish analyst sentiment. The stock shows strong fundamentals with a P/E of 9.2, net income margin of 25.43%, and recent earnings beats in Q4 2025 and Q1 2026. Recent developments include the launch of WA VenueX, a financial platform for digital assets, and recognition as Arizona's #1 bank by Forbes in 2026.
Outlook remains positive with a consensus price target of $93.86, implying 13.6% upside, supported by revenue growth and profitability. Risks include reliance on net interest income, competitive pressures, and macroeconomic sensitivity. Institutional activity shows mixed signals with some trimming positions, but overall analyst consensus is strongly bullish with 79% buy ratings.
XBI, the SPDR S&P Biotech ETF, trades at $159.39, up 0.86% on the day, with a bullish technical signal driven by moving averages. The fund holds 155 biotech stocks, benefiting from strong sector momentum, including a 17% gain in June 2026 (ETF Trends, 2026-07-01). Recent news highlights institutional buying and positive drug trial outcomes fueling the rally.
Outlook: Biotech sector tailwinds from M&A, AI drug discovery, and clinical successes support further upside, but high volatility and policy risks persist. Investors gain diversified exposure to small- and mid-cap biotech innovation, though the 0.35% expense ratio and lack of dividend yield may deter income-focused buyers.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Western Alliance Bancorporation
Western Alliance Bancorporation is a top-performing bank holding company that operates a dual business model: high-touch regional banking and specialized national business lines. It serves niche industries—including technology, life sciences, and homeowners associations—providing sophisticated commercial lending and treasury solutions that bridge the gap between regional service and national scale.
Read more on WAL →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
